ES2386843B1 - NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. - Google Patents
NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. Download PDFInfo
- Publication number
- ES2386843B1 ES2386843B1 ES201130157A ES201130157A ES2386843B1 ES 2386843 B1 ES2386843 B1 ES 2386843B1 ES 201130157 A ES201130157 A ES 201130157A ES 201130157 A ES201130157 A ES 201130157A ES 2386843 B1 ES2386843 B1 ES 2386843B1
- Authority
- ES
- Spain
- Prior art keywords
- application
- art
- state
- composition
- date
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 230000003779 hair growth Effects 0.000 title description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 17
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 15
- 201000004384 Alopecia Diseases 0.000 claims abstract description 13
- 230000003676 hair loss Effects 0.000 claims abstract description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 210000004209 hair Anatomy 0.000 claims abstract description 9
- 208000024963 hair loss Diseases 0.000 claims abstract description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019152 folic acid Nutrition 0.000 claims abstract description 8
- 229960000304 folic acid Drugs 0.000 claims abstract description 8
- 239000011724 folic acid Substances 0.000 claims abstract description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 7
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims abstract description 7
- 235000019393 L-cystine Nutrition 0.000 claims abstract description 7
- 239000004158 L-cystine Substances 0.000 claims abstract description 7
- 229960003067 cystine Drugs 0.000 claims abstract description 7
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 7
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 7
- 239000011701 zinc Substances 0.000 claims abstract description 7
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- 235000016804 zinc Nutrition 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 6
- 239000011720 vitamin B Substances 0.000 claims abstract description 6
- 230000000638 stimulation Effects 0.000 claims abstract 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000021468 vitamin B8 Nutrition 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 244000000231 Sesamum indicum Species 0.000 claims 1
- 235000003434 Sesamum indicum Nutrition 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 229930003451 Vitamin B1 Natural products 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 1
- 235000013734 beta-carotene Nutrition 0.000 claims 1
- 239000011648 beta-carotene Substances 0.000 claims 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 1
- 229960002747 betacarotene Drugs 0.000 claims 1
- 235000021324 borage oil Nutrition 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229960003563 calcium carbonate Drugs 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 claims 1
- 235000014380 magnesium carbonate Nutrition 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 238000006116 polymerization reaction Methods 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960003495 thiamine Drugs 0.000 claims 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 1
- 235000010374 vitamin B1 Nutrition 0.000 claims 1
- 239000011691 vitamin B1 Substances 0.000 claims 1
- 235000019163 vitamin B12 Nutrition 0.000 claims 1
- 235000009492 vitamin B5 Nutrition 0.000 claims 1
- 235000019159 vitamin B9 Nutrition 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 235000006076 zinc citrate Nutrition 0.000 claims 1
- 239000011746 zinc citrate Substances 0.000 claims 1
- 229940068475 zinc citrate Drugs 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 229960001763 zinc sulfate Drugs 0.000 claims 1
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 1
- 230000003698 anagen phase Effects 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229940107889 rogaine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición natural para el tratamiento y prevención de la pérdida de cabello y estimulación del cabello que comprende: vitaminas del complejo B, Zinc, ácido fólico, ácido pantoténico, L-cistina.The present invention relates to a natural composition for the treatment and prevention of hair loss and hair stimulation comprising: B vitamins, Zinc, folic acid, pantothenic acid, L-cystine.
Description
Composición natural para estimular el crecimiento del cabello. CAMPO DE LA INVENCIÓN La presente invención se refiere a una composición natural para estimular el crecimiento y fortalecer el cabello y Natural composition to stimulate hair growth. FIELD OF THE INVENTION The present invention relates to a natural composition to stimulate growth and strengthen hair and
prevenir la pérdida del mismo. ESTADO DE LA TÉCNICA La alopecia se define como la disminución ó pérdida del pelo, localizada o generalizada, temporal ó definitiva de Prevent the loss of it. STATE OF THE TECHNIQUE Alopecia is defined as the decrease or loss of hair, localized or generalized, temporary or definitive of
cualquier tipo u origen. El crecimiento del pelo es cíclico, pasando por 3 etapas: 1ª etapa de crecimiento (anágena) que dura de 2 a 6 años, en la que el pelo crece 1 cm cada mes; seguido de un periodo de reposo o catágeno que dura unas 3 semanas; y Any type or origin. Hair growth is cyclic, going through 3 stages: 1st stage of growth (anagen) that lasts from 2 to 6 years, in which the hair grows 1 cm every month; followed by a resting period or catagen that lasts about 3 weeks; Y
finalmente se alcanza la fase de caída o telógena (cayendo de forma imperceptible entre 80-100 cabellos/día.) que dura de 3 a 4 meses. Existen distintos productos para evitar la pérdida de pelo, entre los que se encuentra el minoxidil, propecia y rogaine finally the fall or telogen phase is reached (falling imperceptibly between 80-100 hairs / day.) It lasts 3 to 4 months. There are different products to prevent hair loss, including minoxidil, propecia and rogaine
entre otros, sin embargo, estos compuestos afectan a las hormonas de tal forma que pueden producir efectos among others, however, these compounds affect hormones in such a way that they can produce effects
secundarios. Existe pues la necesidad de encontrar un tratamiento que estimule y fortalezca el cabello y reduzca la pérdida del mismo sin afectar a las hormonas masculinas. secondary. There is therefore a need to find a treatment that stimulates and strengthens the hair and reduces the loss of same without affecting male hormones.
EXPLICACIÓN DE LA INVENCIÓN La presente invención proporciona una composición que estimula el crecimiento del cabello y previene la pérdida del EXPLANATION OF THE INVENTION The present invention provides a composition that stimulates hair growth and prevents loss of hair.
mismo formada a base de productos naturales de tal forma que evita los problemas planteados en el estado de la técnica. Así pues, en un primer aspecto, la presente invención se refiere a una composición para el tratamiento y prevención same formed based on natural products in such a way that avoids the problems posed in the state of the technique. Thus, in a first aspect, the present invention relates to a composition for treatment and prevention
de la pérdida de cabello que comprende: vitaminas del complejo B, Zinc, ácido fólico, ácido pantoténico, L-cistina. En un aspecto más en particular, las vitaminas del complejo B son seleccionadas de entre vitamina B2, B6 y/o B8. En un aspecto más en particular, la composición de la presente invención además comprende excipientes of hair loss comprising: B vitamins, Zinc, folic acid, pantothenic acid, L-cystine. In a more particular aspect, the B vitamins are selected from vitamin B2, B6 and / or B8. In a more particular aspect, the composition of the present invention further comprises excipients.
aceptables, más en particular, los excipientes son estearato de magnesio y celulosa microcristalina. En un aspecto más en particular, la composición de la presente invención comprende: Acceptable, more particularly, the excipients are magnesium stearate and microcrystalline cellulose. In a more particular aspect, the composition of the present invention comprises:
- 0.41% de vitamina B2 0.41% of vitamin B2
- 0.475 % de vitamina B6 0.475% vitamin B6
- 0.01125 % de vitamina B8 0.01125% of vitamin B8
- 1.5 % en peso de Zinc 1.5% by weight of Zinc
- 0.05 % en peso de ácido fólico 0.05% by weight folic acid
- 2.5 % en peso de ácido pantoténico 2.5% by weight pantothenic acid
- 75 % de L-cistina 75% L-Cystine
- 20 % de estearato de magnesio y celulosa microcristalina 20% magnesium stearate and microcrystalline cellulose
DESCRIPCIÓN DETALLADA DE LA INVENCIÓN EJEMPLO 1: Composición para estimular y fortalecer el cabello y prevenir la pérdida del mismo. DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1: Composition to stimulate and strengthen hair and prevent hair loss.
2 2
- INGREDIENTES INGREDIENTS
- (mg) (mg)
- Vitamina B2 Vitamin B2
- 1.65 1.65
- Vitamina B6 Vitamin B6
- 1.9 1.9
- Vitamina B8 Vitamin B8
- 0.045 0.045
- Zinc Zinc
- 6 6
- Ácido fólico Folic acid
- 0.2 0.2
- Ácido pantoténico Pantothenic acid
- 10 10
- L-cistina L-Cystine
- 300 300
- Estearato de magnesio y celulosa microcristalina Magnesium stearate and microcrystalline cellulose
- 80 80
- TOTAL TOTAL
- 400 400
Los extractos naturales descritos, fueron mezclados con los excipientes mediante los procedimientos conocidos en el estado de la técnica, y posteriormente fueron prensados para comprimirlos. The natural extracts described, were mixed with the excipients by the procedures known in the state of the art, and were subsequently pressed to compress them.
La composición descrita en la presente invención se probó en 36 pacientes con alopecia al que le siguió un estudio doble ciego con 47 pacientes. A los pacientes se les administró dos pastillas diarias durante 3 semanas. La eficacia clínica fue evaluada con métodos estándar, como la preparación de tricogramas y la medición de la densidad capilar antes y después del tratamiento. El estudio piloto demostró una mejoría significativa, con una reducción del 8,3% en 10 la fase telogen, un incremento del 11% en el anagen, y un aumento del 6,9% en la densidad capilar. En el estudio doble ciego (II) el tricograma mostró un descenso significativo del 13,5% en telogen, comparado con los valores patológicos iniciales de referencia. No hubo cambios en el grupo placebo. El disminuido índice del 47,2% en anagen se mejoró un 8%, mientras que el valor principal en el grupo placebo bajó del 47,7% al 39,9%. Además, el porcentaje de pelo anagen displásico mejoró un 7,4%, frente al posterior incremento del 26% en el grupo placebo. The composition described in the present invention was tested in 36 patients with alopecia which was followed by a double-blind study with 47 patients. The patients were given two pills daily for 3 weeks. The clinical efficacy was evaluated with standard methods, such as the preparation of tricograms and the measurement of capillary density before and after treatment. The pilot study showed a significant improvement, with a 8.3% reduction in the telogen phase, an 11% increase in the anagen, and a 6.9% increase in capillary density. In the double-blind (II) study, the tricogram showed a significant decrease of 13.5% in telogen, compared with the initial pathological reference values. There were no changes in the placebo group. The decreased 47.2% rate in anagen was improved by 8%, while the main value in the placebo group dropped from 47.7% to 39.9%. In addition, the percentage of dysplastic anagen hair improved 7.4%, compared to the subsequent 26% increase in the placebo group.
15 Durante la terapia oral no se detectaron efectos secundarios sistémicos. 15 During oral therapy no systemic side effects were detected.
3 3
Claims (9)
- 3.3.
- Composición natural según cualquiera de las reivindicaciones anteriores que comprende excipientes naturalmente aceptables. Natural composition according to any of the preceding claims comprising naturally acceptable excipients.
- 4.Four.
- Composición natural según cualquiera de las reivindicaciones anteriores, donde los excipientes son estearato de magnesio y celulosa microcristalina. Natural composition according to any of the preceding claims, wherein the excipients are magnesium stearate and microcrystalline cellulose.
- 10 5. Composición natural según cualquiera de las reivindicaciones anteriores, caracterizada por que comprende: 0.41% de vitamina B2 10 5. Natural composition according to any of the preceding claims, characterized in that it comprises: 0.41% of vitamin B2
- 0.4750.475
- % de vitamina B6 % of vitamin B6
- 1.51.5
- % en peso de Zinc Zinc weight%
- 15 0.05 % en peso de ácido fólico 15 0.05% by weight folic acid
- Categoría Category
- Documentos citados Reivindicaciones afectadas Documents cited Claims Affected
- A TO
- WO 2009115769 A1 (TAYLOR, ROBERT PETER; LALVANI, KARTHAR SINGH) 24.09.2009, todo el documento. 1-6 WO 2009115769 A1 (TAYLOR, ROBERT PETER; LALVANI, KARTHAR SINGH) 24.09.2009, the whole document. 1-6
- A TO
- FR 2737849 A1 (BOIRON SOCIETÉ ANONYME) 21.02.1997, todo el documento. 1-6 FR 2737849 A1 (BOIRON SOCIETÉ ANONYME) 21.02.1997, the whole document. 1-6
- A TO
- ES 2126136 T3 (JEAN-PIERRE MAURICE OURY) 16.03.1999, todo el documento. 1-6 EN 2126136 T3 (JEAN-PIERRE MAURICE OURY) 16.03.1999, the whole document. 1-6
- Categoría de los documentos citados X: de particular relevancia Y: de particular relevancia combinado con otro/s de la misma categoría A: refleja el estado de la técnica O: referido a divulgación no escrita P: publicado entre la fecha de prioridad y la de presentación de la solicitud E: documento anterior, pero publicado después de la fecha de presentación de la solicitud Category of the documents cited X: of particular relevance Y: of particular relevance combined with other / s of the same category A: reflects the state of the art O: refers to unwritten disclosure P: published between the priority date and the date of priority submission of the application E: previous document, but published after the date of submission of the application
- El presente informe ha sido realizado • para todas las reivindicaciones • para las reivindicaciones nº: This report has been prepared • for all claims • for claims no:
- Fecha de realización del informe 24.10.2011 Date of realization of the report 24.10.2011
- Examinador A. Amaro Roldan Página 1/4 Examiner A. Amaro Roldan Page 1/4
- Novedad (Art. 6.1 LP 11/1986) Novelty (Art. 6.1 LP 11/1986)
- Reivindicaciones Reivindicaciones 1-6 SI NO Claims Claims 1-6 IF NOT
- Actividad inventiva (Art. 8.1 LP11/1986) Inventive activity (Art. 8.1 LP11 / 1986)
- Reivindicaciones Reivindicaciones 1-6 SI NO Claims Claims 1-6 IF NOT
- Documento Document
- Número Publicación o Identificación Fecha Publicación Publication or Identification Number publication date
- D01 D01
- WO 2009115769 A1 (TAYLOR, ROBERT PETER; LALVANI,KARTHAR SINGH) 24.09.2009 WO 2009115769 A1 (TAYLOR, ROBERT PETER; LALVANI, KARTHAR SINGH) 24.09.2009
- D02 D02
- FR 2737849 A1 (BOIRON SOCIETÉ ANONYME) 21.02.1997 FR 2737849 A1 (BOIRON SOCIETÉ ANONYME) 21.02.1997
- D03 D03
- ES 2126136 T3 (JEAN-PIERRE MAURICE OURY) 16.03.1999 ES 2126136 T3 (JEAN-PIERRE MAURICE OURY) 16.03.1999
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201130157A ES2386843B1 (en) | 2011-02-07 | 2011-02-07 | NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201130157A ES2386843B1 (en) | 2011-02-07 | 2011-02-07 | NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2386843A1 ES2386843A1 (en) | 2012-09-03 |
ES2386843B1 true ES2386843B1 (en) | 2013-04-01 |
Family
ID=46671109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201130157A Expired - Fee Related ES2386843B1 (en) | 2011-02-07 | 2011-02-07 | NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2386843B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2708854B1 (en) * | 1993-08-13 | 1995-10-13 | Oury Jean Pierre Maurice | Composition against hair loss and brittle nails. |
FR2737849B1 (en) * | 1995-08-18 | 1997-09-19 | Boiron | ABSORBABLE NUTRITIONAL SUPPLEMENT FOR SENIORS 'DAILY BALANCE |
GB2458466A (en) * | 2008-03-18 | 2009-09-23 | Kartar Singh Lalvani | Composition for hair, skin and nail health maintenance |
-
2011
- 2011-02-07 ES ES201130157A patent/ES2386843B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2386843A1 (en) | 2012-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6827092B2 (en) | Topical composition containing luliconazole | |
AR048181A1 (en) | COMPOSITION OF FUNCTIONAL INGREDIENTS | |
ES2250374T3 (en) | MINOXIDIL BASED PREPARED. | |
EA201790101A1 (en) | ANALOGUES OF PRIDOPIDINE, THEIR PRODUCTION AND APPLICATION | |
WO2005115406A3 (en) | 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents | |
DE602005021770D1 (en) | INDOLE-1-YL-ACETIC DERIVATIVES | |
MX2011012547A (en) | Green tea extracts of improved bioavailability. | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
CY1111484T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIN BESYLIC AND LISINOPRIL BIDRAIN | |
ES2386843B1 (en) | NATURAL COMPOSITION TO STIMULATE HAIR GROWTH. | |
WO2014082027A3 (en) | Antioxidant dietary supplement | |
DE50312661D1 (en) | MEDIUM CONTAINING FOLIC ACID, VITAMIN B6 AND VITAMIN B12, AND ITS USE | |
US9913789B2 (en) | Formulations containing sphinganine | |
AR047765A1 (en) | METHODS AND COMPOSITIONS THAT INCLUDE ILEX | |
EA201892842A1 (en) | PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID | |
CN101460162A (en) | Compositions and kits comprising a melatonin component and a flavanol component | |
ATE419012T1 (en) | USE OF 2,5-DIHYDROXYBENZENESULPHONIC ACID DERIVATIVES IN THE PRODUCTION OF A MEDICATION TO ENHANCE THE EFFECTS OF OTHER MEDICINAL PRODUCTS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | |
ES2541379A1 (en) | Acorn natural cosmetics (Machine-translation by Google Translate, not legally binding) | |
CN109152722A (en) | Composition for oral cavity | |
JP6156371B2 (en) | Hair growth composition | |
ES2367753B1 (en) | WATER SOLUTION TO STOP SMOKING. | |
BR112014001728A2 (en) | formulas comprising highly soluble elements and vitamins for the prevention and improvement of osteoporosis | |
ES2613603A1 (en) | Cosmetic product protector solar (Machine-translation by Google Translate, not legally binding) | |
GB2535989A (en) | Dental product, use of a dental product and methods of use of a dental product | |
MX2009008799A (en) | Pharmaceutical composition on the basis of stachytarpheta sp., a process for obtaining the same and its use for treating vitiligo. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2386843 Country of ref document: ES Kind code of ref document: B1 Effective date: 20130401 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20210915 |